Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seagen Inc.
National Institutes of Health Clinical Center (CC)
University of Chicago
M.D. Anderson Cancer Center
Genmab
Genmab
Genmab
Genmab
Genmab
National Institutes of Health Clinical Center (CC)